Seres Therapeutics Kursziel 55 USD

http://www.serestherapeutics.com/pipeline/products

http://www.finanzen.net/analyse/...ics_Buy-H_C_Wainwright__Co__565873  

• neues 52 Wochen-Tief
  
• weit entfernt von irgendwelchen Analysten Kurszielen
  

 

• neues 52 Wochen-Tief
  

https://seekingalpha.com/article/...conference-presentation-slideshow

 

plant 60 Mio. $ Offering

https://seekingalpha.com/news/...ock-offering-shares-12-percent-hours

 

Details des Offerings

• 26,66 Mio. Aktien zu je 2,25 $
  
• Volumen ~60 Mio. $
  

https://seekingalpha.com/news/...s-therapeutics-prices-stock-offering

 

 

positive Phase3 SER-109 Studienergebnisse

https://ir.serestherapeutics.com/news-releases/...ine-results-ser-109

 

https://xconomy.com/boston/2020/08/10/...e-therapy-scores-in-phase-3/  

Weiter gehts...  

https://seekingalpha.com/news/...on-for-c-diff-candidate-serminus-109  

 

 

 

Phase 2b ECO-RESET Studie von SER-287 (UC) verfehlt den primären Endpunkt

https://ir.serestherapeutics.com/news-releases/...ts-ser-287-phase-2b

 

Trotz des Phase2 Flops von SER-287 sollte man Seres nicht abschreiben. Mit SER-109 haben sie noch ein heißes Eisen im Feuer und werden voraussichtlichtlich demnächst einen Zulasungsantrag stellen. Neben den 175 Mio. $ Vorabzahlung von Nestle könnten bei Zulassung nochmal 125 Mio. $ hinzukommen und umsatzbezogene Meilensteinzahlungen bis zu 225 Mio. $.
https://www.fiercebiotech.com/biotech/...o-as-shares-go-into-freefall

https://www.fool.com/investing/2021/07/22/...stock-is-crashing-today/
https://www.fiercebiotech.com/biotech/...r-rights-to-c-diff-treatment

Zahlen für Q1/21

• Umsatz 6 Mio. $
  
• Verlust 35 Mio. $
  
• Cash 273 Mio. $
  
• MK 651 Mio. $
  

"Following successful SER-109 Phase 3 pivotal results in patients with recurrent C. difficile infection, we continue to enroll an open label study to expand our safety database. We are very pleased with the pace of study enrollment and we anticipate achieving target enrollment during the third quarter of 2021. Completion of the required SER-109 safety database will support a Biologics License Application (BLA) filing, and potentially pave the way for SER-109 to become the first-ever FDA-approved microbiome therapeutic.”

https://ir.serestherapeutics.com/news-releases/...1-financial-results

 

Zahlen für Q2/21

• Umsatz 5 Mio. $
  
• Verlust 48 Mio. $
  
• Cash 229 Mio. $
  
  • +175 Mio. Upfront von Nestlé vom 01. Juli
    
• MK 644 Mio. $
  

– SER-109 open-label study in patients with recurrent C. difficile infection on track to achieve enrollment target in late Q3 2021 –

– SER-109 co-commercialization agreement with Nestlé Health Science provides $310 million in upfront and contingent approval milestones, additional $225 million in contingent sales milestones, and future payments equal to 50% of profits –

https://ir.serestherapeutics.com/news-releases/...1-financial-results

 

https://www.analystratings.com/articles/...n-seres-therapeutics-mcrb/  

 

MK 562 Mio. $, mal sehen ob die 6$ Marke hält, ich vermute das sie kurzfristig fallen wird.  

https://www.finanzen.net/nachricht/aktien/...s-soaring-today-10536700

hab mir mal eine kleine Posi gegönnt  

Seres Therapeutics Molecular Data On SER-109 Looks Good

https://seekingalpha.com/article/...ew-data-rcdi-treatment-looks-good  

https://www.fool.com/investing/2021/11/10/...utic-are-up-more-than-2/  

nach Konsi nimmt die Aktie wieder Fahrt auf!  

https://www.nasdaq.com/market-activity/stocks/mcrb/real-time  

In patients with symptom resolution of C. difficile infection after treatment with standard-of-care antibiotics, oral administration of SER-109 was superior to placebo in reducing the risk of recurrent infection. A 3-day course of SER-109 pills (containing purified bacterial spores) reduced further symptom recurrence: https://www.nejm.org/doi/full/10.1056/NEJMoa2106516

=> Published in NEJM, the highest ranked medical journal in the world  

Seres Therapeutics, armed with new safety data, eyes first FDA approval for a microbiome drug:
https://www.fiercebiotech.com/biotech/...s-not-without-its-challenges